Department of Urology, Gifu University School of Medicine, Gifu, Japan.
Antimicrob Agents Chemother. 2013 Apr;57(4):1772-6. doi: 10.1128/AAC.01956-12. Epub 2013 Jan 28.
The mechanism of quinolone resistance in Mycoplasma genitalium remains poorly understood due to difficulties with in vitro culture, especially of clinical isolates. In this study, to confirm the association between mutations in topoisomerases and antimicrobial susceptibilities to quinolones, ciprofloxacin-resistant mutant strains were selected using the cultivable type strain ATCC 33530. Sequence analysis revealed that the mutant strains harbored mutations in topoisomerase IV: Gly81Cys in ParC, Pro261Thr in ParC, or Asn466Lys in ParE. The MICs of all quinolones tested against the mutant strains were 2- to 16-fold higher than those against the wild-type strain. No cross-resistance was observed with macrolides or tetracyclines. We determined the inhibitory activities of quinolones against DNA gyrase and topoisomerase IV in order to investigate the correlation between antimicrobial susceptibility and inhibitory activity against the target enzymes, considered the primary targets of quinolones. Furthermore, using enzymatic analysis, we confirmed that Gly81Cys in the ParC quinolone resistance-determining region (QRDR) contributed to quinolone resistance. This is the first study to isolate quinolone-resistant mutant strains of M. genitalium harboring substitutions in the parC or parE gene in vitro and to measure the inhibitory activities against the purified topoisomerases of M. genitalium.
由于体外培养困难,尤其是临床分离株的培养困难,导致解脲支原体的喹诺酮耐药机制仍不明确。在这项研究中,为了确认拓扑异构酶突变与喹诺酮类药物药敏性之间的关联,使用可培养的标准株 ATCC 33530 选择了环丙沙星耐药突变株。序列分析显示,突变株在拓扑异构酶 IV 中携带突变:ParC 中的 Gly81Cys、ParC 中的 Pro261Thr 或 ParE 中的 Asn466Lys。与野生型菌株相比,所有测试的喹诺酮类药物对突变株的 MIC 值均升高了 2 至 16 倍。与大环内酯类或四环素类药物无交叉耐药性。为了研究抗菌敏感性与靶酶抑制活性之间的相关性,我们测定了喹诺酮类药物对 DNA 回旋酶和拓扑异构酶 IV 的抑制活性,这两种酶被认为是喹诺酮类药物的主要作用靶位。此外,通过酶分析,我们证实 ParC 喹诺酮耐药决定区(QRDR)中的 Gly81Cys 导致了喹诺酮耐药。这是首次在体外分离出携带 parC 或 parE 基因突变的耐喹诺酮解脲支原体突变株,并测定了对解脲支原体纯化拓扑异构酶的抑制活性的研究。